PainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 34,000 shares, a decrease of 47.5% from the January 31st total of 64,800 shares. Based on an average daily trading volume, of 3,330,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 4.0% of the shares of the company are sold short.
Institutional Investors Weigh In On PainReform
An institutional investor recently bought a new position in PainReform stock. Apollon Wealth Management LLC bought a new stake in PainReform Ltd. (NASDAQ:PRFX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned approximately 9.23% of PainReform as of its most recent SEC filing. 37.28% of the stock is currently owned by institutional investors and hedge funds.
PainReform Stock Down 1.6 %
NASDAQ PRFX traded down $0.05 during trading hours on Monday, hitting $3.10. The company had a trading volume of 50,609 shares, compared to its average volume of 1,680,770. PainReform has a fifty-two week low of $1.73 and a fifty-two week high of $61.20. The firm has a market cap of $449,500.00, a P/E ratio of -0.02 and a beta of 0.64. The business has a fifty day simple moving average of $3.25 and a 200-day simple moving average of $2.86.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Further Reading
- Five stocks we like better than PainReform
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Should You Invest in Penny Stocks?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- ESG Stocks, What Investors Should Know
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
